A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
NCT ID: NCT02859207
Last Updated: 2017-06-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
32 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-08-31
Study Completion Date
2017-01-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of the study is to evaluate the effects of hepatic impairment on the pharmacokinetics (PK) of E2609 after a single dose administration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
NCT01600859
Alzheimer's Disease
COMPLETED
PHASE1
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort
NCT01294540
Alzheimer's Disease
COMPLETED
PHASE1
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
NCT02322021
Alzheimer Disease
Dementia, Alzheimer Type
TERMINATED
PHASE2
An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption
NCT01716897
Alzheimer's Disease
COMPLETED
PHASE1
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
NCT06602258
Alzheimer's Disease
ACTIVE_NOT_RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Early Alzheimer's Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Participants with mild hepatic impairment (Child-Pugh class A).
Group Type
EXPERIMENTAL
E2609
Intervention Type
DRUG
Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
Cohort 1C
Healthy participants (control) matched to participants in Cohort 1.
Group Type
EXPERIMENTAL
E2609
Intervention Type
DRUG
Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
Cohort 2
Participants with moderate hepatic impairment (Child-Pugh class B)
Group Type
EXPERIMENTAL
E2609
Intervention Type
DRUG
Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
Cohort 2C
Healthy participants (control) matched to participants in Cohort 2
Group Type
EXPERIMENTAL
E2609
Intervention Type
DRUG
Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
E2609
Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Nonsmoking, male or female, ≥18 years and ≤70 years of age at the time of informed consent, and with body mass index (BMI) of up to 40 kg/m2, inclusive.
2. For Cohorts 1 and 2: stable mild or moderate hepatic impairment conforming to Child-Pugh class A or B, respectively, documented by medical history, physical examination and 1 or more of the following diagnostic procedures documented in the medical notes: liver biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), ultrasound, radionuclide liver/spleen scan, or abdominal laparoscopy. Participants whose liver imaging was done more than 1 year ago or previous results were not available, should have a liver ultrasound scan to ensure that the liver structure is consistent with the diagnosis of hepatic impairment and that there are no exclusionary features.
3. For Cohorts 1C and 2C: healthy participants matched to participants with mild or moderate hepatic impairment with regard to age (±10 years), body weight (±20%), and gender; and as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram (ECG), and clinical laboratory determinations.
2. For Cohorts 1 and 2: stable mild or moderate hepatic impairment conforming to Child-Pugh class A or B, respectively, documented by medical history, physical examination and 1 or more of the following diagnostic procedures documented in the medical notes: liver biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), ultrasound, radionuclide liver/spleen scan, or abdominal laparoscopy. Participants whose liver imaging was done more than 1 year ago or previous results were not available, should have a liver ultrasound scan to ensure that the liver structure is consistent with the diagnosis of hepatic impairment and that there are no exclusionary features.
3. For Cohorts 1C and 2C: healthy participants matched to participants with mild or moderate hepatic impairment with regard to age (±10 years), body weight (±20%), and gender; and as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram (ECG), and clinical laboratory determinations.
Exclusion Criteria
For all Participants (Cohorts 1, 2, 1C, and 2C)
1. Females participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin \[ß-hCG\] test. A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the dose of study drug.
2. Females of childbearing potential who:
* Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method \[such as condom plus diaphragm with spermicide\], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period or for 28 days after study drug discontinuation.
* Are currently abstinent and do not agree to use a double-barrier method (as previously described) or refrain from sexual activity during the study period or for 28 days after study drug discontinuation .
* Are using hormonal contraceptives but are not on a stable dose of the same hormonal contraceptive product except those containing estradiol for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study or for 28 days after study drug discontinuation.
* Are using estradiol-containing hormonal contraceptives within 4 weeks before dosing (NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal \[amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause\] or have been sterilized surgically \[eg, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy; all with surgery at least 1 month before dosing\]).
3. Males who have not had a successful vasectomy (unconfirmed azoospermia) or they and their female partners do not meet the criteria specified in exclusion criterion 2 (eg, unwilling to refrain from sexual activity, not of childbearing potential or practicing highly effective contraception throughout the study period or for 28 days after study drug discontinuation).
4. Inability to tolerate oral medication.
5. Inability to be venipunctured and/or tolerate venous access. For Hepatically Impaired Participants (Cohorts 1 and 2)
6. Any significant acute medical illness (such as new conditions or exacerbation or pre-existing conditions) within 4 weeks before dosing.
7. Medical conditions which are not adequately and stably controlled on stable doses of medications or which, in the clinical opinion of the investigator, may interfere with study procedures or participant safety within 4 weeks before dosing; eg, psychiatric disorders and disorders of the gastrointestinal tract, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism. Participants with history of seizures during adulthood are excluded. Participants with a history of Gilbert's syndrome are excluded.
8. History of esophageal and gastric variceal bleeding within the past 3 months unless the participant has completed a course of endoscopic therapy with the appropriate documentation (eg, endoscopy report) of successful ablation of esophageal varices; participants with esophageal varices may be included if not bleeding within the past 3 months or have been treated adequately by ablation therapy.
9. Spontaneous bacterial peritonitis within 3 months before dosing.
10. Treatment with plasmapheresis within 6 months before dosing.
11. Primarily cholestatic liver diseases (eg, primary biliary cirrhosis or primary sclerosing cholangitis).
12. Current or recent (within 3 months before Screening) history of significant gastrointestinal disease other than that secondary to hepatic impairment.
13. Autoimmune liver disease.
14. Active alcoholic hepatitis determined either clinically or by histology per the discretion of the investigator.
15. History of hepatoma or metastatic disease of the liver.
16. Presence of severe ascites or edema.
17. Presence of hepatopulmonary syndrome or hydrothorax, or hepatorenal syndrome.
18. Known significant bleeding diathesis that could preclude multiple venipunctures (International Normalized Ratio \[INR\] \>2.5).
19. Any major surgery within 4 weeks before dosing.
20. Any history of abdominal surgery that may affect the pharmacokinetic (PK) of E2609 (eg, hepatectomy, nephrectomy, digestive organ resection, transjugular intrahepatic portosystemic shunt \[TIPS\]) at Screening or Baseline (history of cholecystectomy need not be exclusionary).
21. Donation of blood or plasma within 4 weeks before dosing.
22. Receipt of blood or blood products within 4 weeks before dosing.
23. Known to be human immunodeficiency virus (HIV)-positive at Screening.
24. Creatinine clearance \<60 mL/min at Screening or Baseline, as calculated using Cockroft and Gault equation.
25. Known history of clinically significant drug allergy at Screening.
26. Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening.
27. History of drug or alcohol dependency or abuse within 4 weeks before Screening, or those who have a positive urine drug test or breath (or urine) alcohol test at Screening or Baseline unless a prescribed medication for the underlying condition is the cause of the positive urine screen.
28. A prolonged QT/QTc interval (QTc Fridericia \[QTcF\] \>480 ms) demonstrated on the ECG at Screening or Baseline. A history of risk factors for torsade de pointes (eg, heart failure, hypokalemia, family history of long QT Syndrome).
29. Currently enrolled in another clinical study or used any investigational drug or device within 28 days or 5× the half-life of the investigational drug, whichever is longer, preceding informed consent.
30. Intake of nutritional supplements, juice, and herbal preparations or other foods or beverages that may affect the various drug metabolizing enzymes and transporters (eg, alcohol, grapefruit, grapefruit juice, grapefruit-containing beverages, apple or orange juice, vegetables from the mustard green family \[eg, kale, broccoli, watercress, collard greens, kohlrabi, brussel sprouts, mustard\], and charbroiled meats) within 1 week before dosing.
31. Intake of herbal preparations containing St. John's Wort within 4 weeks before dosing .
32. Engagement in strenuous exercise within 2 weeks before Baseline.
For Healthy Participants (Cohorts 1C and 2C)
33. Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing.
34. Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; eg, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system), or participants who have a congenital abnormality in metabolism. Participants with history of seizures in adulthood are excluded.
35. Any history of gastrointestinal surgery that may affect the drug absorption (eg, hepatectomy, nephrotomy, digestive organ resection, but not cholecystectomy) at Screening.
36. Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital sign assessments, ECG finding, or laboratory test results that require medical treatment at Screening.
37. A prolonged QT/QTc interval (QTcF \>450 ms) demonstrated on ECG at Screening or Baseline. A history of risk factors for torsade de pointes (eg, heart failure, hypokalemia, family history of long QT Syndrome), or the use of concomitant medications that prolonged the QT/QTc interval.
38. Known history of clinically significant drug allergy at Screening.
39. Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening.
40. Known to be HIV-positive at Screening.
41. Active viral hepatitis (B or C) as demonstrated by positive serology at Screening.
42. History of drug or alcohol dependency or abuse within the 1 year before Screening, or those who have a positive urine drug test or breath (or urine) alcohol test at Screening or Baseline.
43. Intake of nutritional supplements, juice, and herbal preparations or other foods or beverages that may affect the various drug metabolizing enzymes and transporters (eg, alcohol, grapefruit, grapefruit juice, grapefruit-containing beverages, apple or orange juice, vegetables from the mustard green family \[eg, kale, broccoli, watercress, collard greens, kohlrabi, brussel sprouts, mustard\], and charbroiled meats) within 1 week before dosing.
44. Intake of herbal preparations containing St. John's wort within 4 weeks before dosing.
46. Intake of over-the-counter (OTC) medications within 2 weeks or 5 half-lives, whichever is longer, before dosing.
47. Currently enrolled in another clinical study or used any investigational drug or device within 28 days or 5x the half-life of the investigational drug, whichever is longer, preceding informed consent.
48. Receipt of blood or blood products within 4 weeks, or donation of blood within 4 weeks, of dosing.
49. Engagement in strenuous exercise within 2 weeks before Baseline.
1. Females participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin \[ß-hCG\] test. A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the dose of study drug.
2. Females of childbearing potential who:
* Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method \[such as condom plus diaphragm with spermicide\], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period or for 28 days after study drug discontinuation.
* Are currently abstinent and do not agree to use a double-barrier method (as previously described) or refrain from sexual activity during the study period or for 28 days after study drug discontinuation .
* Are using hormonal contraceptives but are not on a stable dose of the same hormonal contraceptive product except those containing estradiol for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study or for 28 days after study drug discontinuation.
* Are using estradiol-containing hormonal contraceptives within 4 weeks before dosing (NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal \[amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause\] or have been sterilized surgically \[eg, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy; all with surgery at least 1 month before dosing\]).
3. Males who have not had a successful vasectomy (unconfirmed azoospermia) or they and their female partners do not meet the criteria specified in exclusion criterion 2 (eg, unwilling to refrain from sexual activity, not of childbearing potential or practicing highly effective contraception throughout the study period or for 28 days after study drug discontinuation).
4. Inability to tolerate oral medication.
5. Inability to be venipunctured and/or tolerate venous access. For Hepatically Impaired Participants (Cohorts 1 and 2)
6. Any significant acute medical illness (such as new conditions or exacerbation or pre-existing conditions) within 4 weeks before dosing.
7. Medical conditions which are not adequately and stably controlled on stable doses of medications or which, in the clinical opinion of the investigator, may interfere with study procedures or participant safety within 4 weeks before dosing; eg, psychiatric disorders and disorders of the gastrointestinal tract, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism. Participants with history of seizures during adulthood are excluded. Participants with a history of Gilbert's syndrome are excluded.
8. History of esophageal and gastric variceal bleeding within the past 3 months unless the participant has completed a course of endoscopic therapy with the appropriate documentation (eg, endoscopy report) of successful ablation of esophageal varices; participants with esophageal varices may be included if not bleeding within the past 3 months or have been treated adequately by ablation therapy.
9. Spontaneous bacterial peritonitis within 3 months before dosing.
10. Treatment with plasmapheresis within 6 months before dosing.
11. Primarily cholestatic liver diseases (eg, primary biliary cirrhosis or primary sclerosing cholangitis).
12. Current or recent (within 3 months before Screening) history of significant gastrointestinal disease other than that secondary to hepatic impairment.
13. Autoimmune liver disease.
14. Active alcoholic hepatitis determined either clinically or by histology per the discretion of the investigator.
15. History of hepatoma or metastatic disease of the liver.
16. Presence of severe ascites or edema.
17. Presence of hepatopulmonary syndrome or hydrothorax, or hepatorenal syndrome.
18. Known significant bleeding diathesis that could preclude multiple venipunctures (International Normalized Ratio \[INR\] \>2.5).
19. Any major surgery within 4 weeks before dosing.
20. Any history of abdominal surgery that may affect the pharmacokinetic (PK) of E2609 (eg, hepatectomy, nephrectomy, digestive organ resection, transjugular intrahepatic portosystemic shunt \[TIPS\]) at Screening or Baseline (history of cholecystectomy need not be exclusionary).
21. Donation of blood or plasma within 4 weeks before dosing.
22. Receipt of blood or blood products within 4 weeks before dosing.
23. Known to be human immunodeficiency virus (HIV)-positive at Screening.
24. Creatinine clearance \<60 mL/min at Screening or Baseline, as calculated using Cockroft and Gault equation.
25. Known history of clinically significant drug allergy at Screening.
26. Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening.
27. History of drug or alcohol dependency or abuse within 4 weeks before Screening, or those who have a positive urine drug test or breath (or urine) alcohol test at Screening or Baseline unless a prescribed medication for the underlying condition is the cause of the positive urine screen.
28. A prolonged QT/QTc interval (QTc Fridericia \[QTcF\] \>480 ms) demonstrated on the ECG at Screening or Baseline. A history of risk factors for torsade de pointes (eg, heart failure, hypokalemia, family history of long QT Syndrome).
29. Currently enrolled in another clinical study or used any investigational drug or device within 28 days or 5× the half-life of the investigational drug, whichever is longer, preceding informed consent.
30. Intake of nutritional supplements, juice, and herbal preparations or other foods or beverages that may affect the various drug metabolizing enzymes and transporters (eg, alcohol, grapefruit, grapefruit juice, grapefruit-containing beverages, apple or orange juice, vegetables from the mustard green family \[eg, kale, broccoli, watercress, collard greens, kohlrabi, brussel sprouts, mustard\], and charbroiled meats) within 1 week before dosing.
31. Intake of herbal preparations containing St. John's Wort within 4 weeks before dosing .
32. Engagement in strenuous exercise within 2 weeks before Baseline.
For Healthy Participants (Cohorts 1C and 2C)
33. Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing.
34. Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; eg, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system), or participants who have a congenital abnormality in metabolism. Participants with history of seizures in adulthood are excluded.
35. Any history of gastrointestinal surgery that may affect the drug absorption (eg, hepatectomy, nephrotomy, digestive organ resection, but not cholecystectomy) at Screening.
36. Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital sign assessments, ECG finding, or laboratory test results that require medical treatment at Screening.
37. A prolonged QT/QTc interval (QTcF \>450 ms) demonstrated on ECG at Screening or Baseline. A history of risk factors for torsade de pointes (eg, heart failure, hypokalemia, family history of long QT Syndrome), or the use of concomitant medications that prolonged the QT/QTc interval.
38. Known history of clinically significant drug allergy at Screening.
39. Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening.
40. Known to be HIV-positive at Screening.
41. Active viral hepatitis (B or C) as demonstrated by positive serology at Screening.
42. History of drug or alcohol dependency or abuse within the 1 year before Screening, or those who have a positive urine drug test or breath (or urine) alcohol test at Screening or Baseline.
43. Intake of nutritional supplements, juice, and herbal preparations or other foods or beverages that may affect the various drug metabolizing enzymes and transporters (eg, alcohol, grapefruit, grapefruit juice, grapefruit-containing beverages, apple or orange juice, vegetables from the mustard green family \[eg, kale, broccoli, watercress, collard greens, kohlrabi, brussel sprouts, mustard\], and charbroiled meats) within 1 week before dosing.
44. Intake of herbal preparations containing St. John's wort within 4 weeks before dosing.
46. Intake of over-the-counter (OTC) medications within 2 weeks or 5 half-lives, whichever is longer, before dosing.
47. Currently enrolled in another clinical study or used any investigational drug or device within 28 days or 5x the half-life of the investigational drug, whichever is longer, preceding informed consent.
48. Receipt of blood or blood products within 4 weeks, or donation of blood within 4 weeks, of dosing.
49. Engagement in strenuous exercise within 2 weeks before Baseline.
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Miami, Florida, United States
Site Status
Orlando, Florida, United States
Site Status
Minneapolis, Minnesota, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E2609-A001-103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects
NCT01221259
COMPLETED
PHASE1
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
NCT05269394
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
Study of the Effect of SR57667B in Patients With Alzheimer's Disease
NCT00285025
COMPLETED
PHASE2
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
NCT01266525
COMPLETED
PHASE2
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
NCT02910739
COMPLETED
PHASE1
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
NCT01760005
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects
NCT01903824
COMPLETED
PHASE1
A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease
NCT02353598
COMPLETED
PHASE1
A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
NCT04764669
COMPLETED
PHASE2
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
NCT02820896
COMPLETED
PHASE1
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
NCT06881836
RECRUITING
PHASE2
Monitoring Drug Efficacy in Patients with Alzheimer's Disease
NCT05801380
RECRUITING
Effect of Insulin Sensitizer Metformin on AD Biomarkers
NCT01965756
COMPLETED
PHASE2
BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
NCT02788513
COMPLETED
PHASE2
A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
NCT02660983
COMPLETED
PHASE4
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
NCT01082965
TERMINATED
NA
The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil
NCT01024660
COMPLETED
EARLY_PHASE1
Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill
NCT06597058
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
NCT04971733
COMPLETED
PHASE1/PHASE2
Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
NCT02573740
TERMINATED
PHASE1
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355
NCT03802162
COMPLETED
PHASE1
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
NCT02079909
COMPLETED
PHASE2
Metformin in Alzheimer's Dementia Prevention
NCT04098666
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3